SwePub
Tyck till om SwePub Sök här!
Sök i SwePub databas

  Extended search

Träfflista för sökning "WFRF:(Smith Ulf 1943) ;lar1:(cth)"

Search: WFRF:(Smith Ulf 1943) > Chalmers University of Technology

  • Result 1-10 of 11
Sort/group result
   
EnumerationReferenceCoverFind
1.
  • Johansson, Helena, 1981, et al. (author)
  • High serum adiponectin predicts incident fractures in elderly men: Osteoporotic fractures in men (MrOS) Sweden
  • 2012
  • In: Journal of Bone and Mineral Research. - : Wiley. - 1523-4681 .- 0884-0431. ; 27:6, s. 1390-1396
  • Journal article (peer-reviewed)abstract
    • Adipocytes and osteoblasts share a common progenitor, and there is, therefore, potential for both autocrine and endocrine effects of adiponectin on skeletal metabolism. The aim of the present study was to determine whether high serum adiponectin was associated with an increased risk of fracture in elderly men. We studied the relationship between serum adiponectin and the risk of fracture in 999 elderly men drawn from the general population and recruited to the Osteoporotic Fractures in Men (MrOS) study in Gothenburg, Sweden. Baseline data included general health questionnaires, lifestyle questionnaires, body mass index (BMI), bone mineral density (BMD), serum adiponectin, osteocalcin, and leptin. Men were followed for up to 7.4 years (average, 5.2 years). Poisson regression was used to investigate the relationship between serum adiponectin, other risk variables and the time-to-event hazard function of fracture. Median levels of serum adiponectin at baseline were 10.4 mu g/mL (interquartile range, 7.714.3). During follow-up, 150 men sustained one or more fractures. The risk of fracture increased in parallel with increasing serum adiponectin (hazard ratio [HR]/SD, 1.46; 95% confidence interval [CI], 1.231.72) and persisted after multivariate-adjusted analysis (HR/SD, 1.30; 95% CI, 1.091.55). Serum adiponectin shows graded stepwise association with a significant excess risk of fracture in elderly men that was independent of several other risk factors for fracture. Its measurement holds promise as a risk factor for fracture in men. (C) 2012 American Society for Bone and Mineral Research.
  •  
2.
  • Grunberg, J. R., et al. (author)
  • CCN5/WISP2 and metabolic diseases
  • 2018
  • In: Journal of Cell Communication and Signaling. - : Springer Science and Business Media LLC. - 1873-9601 .- 1873-961X. ; 12:1, s. 309-318
  • Journal article (peer-reviewed)abstract
    • Obesity and type 2 diabetes increase worldwide at an epidemic rate. It is expected that by the year 2030 around 500 million people will have diabetes; predominantly type 2 diabetes. The CCN family of proteins has become of interest in both metabolic and other common human diseases because of their effects on mesenchymal stem cell (MSCs) proliferation and differentiation as well as being important regulators of fibrosis. We here review current knowledge of the WNT1 inducible signaling pathway protein 2 (CCN5/WISP2). It has been shown to be an important regulator of both these processes through effects on both the canonical WNT and the TGF ss pathways. It is also under normal regulation by the adipogenic commitment factor BMP4, in contrast to conventional canonical WNT ligands, and allows MSCs to undergo normal adipose cell differentiation. CCN5/WISP2 is highly expressed in, and secreted by, MSCs and is an important regulator of MSCs growth. In a transgenic mouse model overexpressing CCN5/WISP2 in the adipose tissue, we have shown that it is secreted and circulating in the blood, the mice develop hypercellular white and brown adipose tissue, have increased lean body mass and enlarged hypercellular hearts. Obese transgenic mice had improved insulin sensitivity. Interestingly, the anti-fibrotic effect of CCN5/WISP2 is protective against heart failure by inhibition of the TGF ss pathway. Understanding how CCN5/WISP2 is regulated and signals is important and may be useful for developing new treatment strategies in obesity and metabolic diseases and it can also be a target in regenerative medicine.
  •  
3.
  • Lee, Sunjae, et al. (author)
  • Integrated Network Analysis Reveals an Association between Plasma Mannose Levels and Insulin Resistance
  • 2016
  • In: Cell Metabolism. - : Elsevier BV. - 1550-4131 .- 1932-7420. ; 24:1, s. 172-184
  • Journal article (peer-reviewed)abstract
    • To investigate the biological processes that are altered in obese subjects, we generated cell-specific integrated networks (INs) by merging genome-scale metabolic, transcriptional regulatory and protein-protein interaction networks. We performed genome-wide transcriptomics analysis to determine the global gene expression changes in the liver and three adipose tissues from obese subjects undergoing bariatric surgery and integrated these data into the cell-specific INs. We found dysregulations in mannose metabolism in obese subjects and validated our predictions by detecting mannose levels in the plasma of the lean and obese subjects. We observed significant correlations between plasma mannose levels, BMI, and insulin resistance (IR). We also measured plasma mannose levels of the subjects in two additional different cohorts and observed that an increased plasma mannose level was associated with IR and insulin secretion. We finally identified mannose as one of the best plasma metabolites in explaining the variance in obesity-independent IR.
  •  
4.
  • Lee, SangWook, et al. (author)
  • Network analyses identify liver-specific targets for treating liver diseases
  • 2017
  • In: Molecular Systems Biology. - : EMBO. - 1744-4292. ; 13:8
  • Journal article (peer-reviewed)abstract
    • We performed integrative network analyses to identify targets that can be used for effectively treating liver diseases with minimal side effects. We first generated co-expression networks (CNs) for 46 human tissues and liver cancer to explore the functional relationships between genes and examined the overlap between functional and physical interactions. Since increased de novo lipogenesis is a characteristic of nonalcoholic fatty liver disease (NAFLD) and hepatocellular carcinoma (HCC), we investigated the liver-specific genes co-expressed with fatty acid synthase (FASN). CN analyses predicted that inhibition of these liver-specific genes decreases FASN expression. Experiments in human cancer cell lines, mouse liver samples, and primary human hepatocytes validated our predictions by demonstrating functional relationships between these liver genes, and showing that their inhibition decreases cell growth and liver fat content. In conclusion, we identified liver-specific genes linked to NAFLD pathogenesis, such as pyruvate kinase liver and red blood cell (PKLR), or to HCC pathogenesis, such as PKLR, patatin-like phospholipase domain containing 3 (PNPLA3), and proprotein convertase subtilisin/kexin type 9 (PCSK9), all of which are potential targets for drug development.
  •  
5.
  • Mardinoglu, Adil, 1982, et al. (author)
  • Confounding effects of metformin on the human gut microbiome in Type 2 diabetes
  • 2016
  • In: Cell Metabolism. - : Elsevier BV. - 1550-4131 .- 1932-7420. ; 23:1, s. 10-12
  • Journal article (peer-reviewed)abstract
    • Type 2 diabetes (T2D) is associated with dysbiosis of the gut microbiota, though diabetes treatment regimens, including metformin, may confound the results. Forslund et al. (2015) identify distinct disease and drug signatures and highlight the importance of adjusting for treatment when investigating how T2D influences the human gut microbiome.
  •  
6.
  • Mardinoglu, Adil, 1982, et al. (author)
  • Elevated Plasma Levels of 3-Hydroxyisobutyric Acid Are Associated With Incident Type 2 Diabetes
  • 2018
  • In: Ebiomedicine. - : Elsevier BV. - 2352-3964. ; 27, s. 151-155
  • Journal article (peer-reviewed)abstract
    • Branched-chain amino acids (BCAAs) metabolite, 3-Hydroxyisobutyric acid (3-HIB) has been identified as a secreted mediator of endothelial cell fatty acid transport and insulin resistance (IR) using animal models. To identify if 3-HIB is a marker of human IR and future risk of developing Type 2 diabetes (T2D), we measured plasma levels of 3-HIB and associated metabolites in around 10,000 extensively phenotyped individuals. The levels of 3-HIB were increased in obesity but not robustly associated with degree of IR after adjusting for BMI. Nevertheless, also after adjusting for obesity and plasma BCAA, 3-HIB levels were associated with future risk of incident T2D. We also examined the effect of 3-HIB on fatty acid uptake in human cells and found that both HUVEC and human cardiac endothelial cells respond to 3-HIB whereas human adipose tissue-derived endothelial cells do not respond to 3-HIB. In conclusion, we found that increased plasma level of 3-HIB is a marker of future risk of T2D and 3-HIB may be important for the regulation of metabolic flexibility in heart and muscles.
  •  
7.
  • Mardinoglu, Adil, 1982, et al. (author)
  • Personal model-assisted identification of NAD(+) and glutathione metabolism as intervention target in NAFLD
  • 2017
  • In: Molecular Systems Biology. - : EMBO. - 1744-4292. ; 13:3
  • Journal article (peer-reviewed)abstract
    • To elucidate the molecular mechanisms underlying non-alcoholic fatty liver disease (NAFLD), we recruited 86 subjects with varying degrees of hepatic steatosis (HS). We obtained experimental data on lipoprotein fluxes and used these individual measurements as personalized constraints of a hepatocyte genome-scale metabolic model to investigate metabolic differences in liver, taking into account its interactions with other tissues. Our systems level analysis predicted an altered demand for NAD(+) and glutathione (GSH) in subjects with high HS. Our analysis and metabolomic measurements showed that plasma levels of glycine, serine, and associated metabolites are negatively correlated with HS, suggesting that these GSH metabolism precursors might be limiting. Quantification of the hepatic expression levels of the associated enzymes further pointed to altered de novo GSH synthesis. To assess the effect of GSH and NAD(+) repletion on the development of NAFLD, we added precursors for GSH and NAD(+) biosynthesis to the Western diet and demonstrated that supplementation prevents HS in mice. In a proof-of-concept human study, we found improved liver function and decreased HS after supplementation with serine (a precursor to glycine) and hereby propose a strategy for NAFLD treatment.
  •  
8.
  • Mardinoglu, Adil, 1982, et al. (author)
  • Plasma Mannose Levels Are Associated with Incident Type 2 Diabetes and Cardiovascular Disease
  • 2017
  • In: Cell Metabolism. - : Elsevier BV. - 1932-7420 .- 1550-4131. ; 26:2, s. 281-283
  • Journal article (other academic/artistic)abstract
    • Plasma mannose levels are elevated in subjects with insulin resistance independently of obesity. Here, we found that elevated plasma mannose levels are strong markers of future risk of several chronic diseases including T2D, CVD, and albuminuria, and that it may contribute to their development rather than just being a novel biomarker.
  •  
9.
  • Mardinoglu, Adil, 1982, et al. (author)
  • Systems biology in hepatology: approaches and applications
  • 2018
  • In: Nature Reviews Gastroenterology & Hepatology. - : Springer Science and Business Media LLC. - 1759-5045 .- 1759-5053. ; 15:6, s. 365-377
  • Journal article (peer-reviewed)abstract
    • Detailed insights into the biological functions of the liver and an understanding of its crosstalk with other human tissues and the gut microbiota can be used to develop novel strategies for the prevention and treatment of liver-associated diseases, including fatty liver disease, cirrhosis, hepatocellular carcinoma and type 2 diabetes mellitus. Biological network models, including metabolic, transcriptional regulatory, protein-protein interaction, signalling and co-expression networks, can provide a scaffold for studying the biological pathways operating in the liver in connection with disease development in a systematic manner. Here, we review studies in which biological network models were used to integrate multiomics data to advance our understanding of the pathophysiological responses of complex liver diseases. We also discuss how this mechanistic approach can contribute to the discovery of potential biomarkers and novel drug targets, which might lead to the design of targeted and improved treatment strategies. Finally, we present a roadmap for the successful integration of models of the liver and other human tissues with the gut microbiota to simulate whole-body metabolic functions in health and disease.
  •  
10.
  • Palming, Jenny, 1975, et al. (author)
  • Plasma cells and Fc receptors in human adipose tissue--lipogenic and anti-inflammatory effects of immunoglobulins on adipocytes
  • 2006
  • In: Biochem Biophys Res Commun. - : Elsevier BV. - 0006-291X .- 1090-2104. ; 343:1, s. 43-8
  • Journal article (peer-reviewed)abstract
    • We have previously reported high immunoglobulin expression in human omental adipose tissue. The aim of this work was to investigate plasma cell density and Fc receptor (FcR) expression in human adipose tissue depots and in vitro effects of immunoglobulins on adipocyte function. Plasma cell density was higher in the visceral compared to the subcutaneous depot (10.0+/-1.56% and 5.2+/-0.98%, respectively, n=20, p<0.05). Microarray analysis revealed expression of four FcR genes in adipose tissue; FCGR2A, FCGR2B, FCER1G, and FCGRT. FCGR2A was highly expressed in adipocytes in both depots and this was verified by immunohistochemistry. Expression of IL-1beta and IL-6 was markedly reduced in adipocytes after incubation with the Fc moiety of immunoglobulin G (Fc) (p<0.01). Furthermore, Fc stimulated adipocyte lipogenesis as potently as insulin (p<0.05), but did not influence lipolysis. In conclusion, immunoglobulins produced by plasma cells in human adipose tissue could influence adipocyte metabolism and cytokine production.
  •  
Skapa referenser, mejla, bekava och länka
  • Result 1-10 of 11
Type of publication
journal article (11)
Type of content
peer-reviewed (10)
other academic/artistic (1)
Author/Editor
Smith, Ulf, 1943 (11)
Mardinoglu, Adil, 19 ... (8)
Borén, Jan, 1963 (7)
Nielsen, Jens B, 196 ... (4)
Uhlén, Mathias (4)
Zhang, C. (4)
show more...
Ferrannini, E (3)
Laakso, M. (3)
Bluher, M. (3)
Piening, B. D. (3)
Langenberg, C. (2)
Wareham, N. J. (2)
Lee, Sunjae (2)
Björnson, Elias, 198 ... (2)
Ståhlman, Marcus, 19 ... (2)
Stancakova, A. (2)
Klevstig, Martina (2)
Lee, S (1)
Karlsson, Magnus (1)
Marschall, Hanns-Ulr ... (1)
Zhang, Cheng (1)
Bäckhed, Fredrik, 19 ... (1)
Lorentzon, Mattias, ... (1)
Johansson, Helena, 1 ... (1)
Jennische, Eva, 1949 (1)
Mishra, T (1)
Adiels, Martin, 1976 (1)
Taskinen, M. R. (1)
Soderlund, S (1)
Hakkarainen, A. (1)
Lundbom, N. (1)
Ohlsson, Claes, 1965 (1)
Odén, Anders, 1942 (1)
Carlsson, Lena M S, ... (1)
Hammarstedt, Ann, 19 ... (1)
Rego, S (1)
Grøtli, Morten, 1966 (1)
Gerstein, M (1)
Mellström, Dan, 1945 (1)
Kuusisto, J. (1)
Elsässer, Simon J. (1)
Lönn, Malin, 1959 (1)
Gabrielsson, Britt, ... (1)
Lerner, Ulf H (1)
Carlsson, Björn, 195 ... (1)
Hedjazifar, Shahram, ... (1)
Ljunggren, Östen (1)
Hallström, Björn M. (1)
Snyder, M. P. (1)
Hallstrom, B. M. (1)
show less...
University
University of Gothenburg (11)
Royal Institute of Technology (8)
Uppsala University (2)
Umeå University (1)
Lund University (1)
show more...
Karolinska Institutet (1)
show less...
Language
English (11)
Research subject (UKÄ/SCB)
Medical and Health Sciences (10)
Natural sciences (7)

Year

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view